TLR5 and influenza: A Phase III clinical trial shows that VAX125, a recombinant influenza vaccine consisting of flagellin (a TLR5 agonist), elicits vigorous responses against native virions at a relatively low dose of influenza hemagglutinin antigen, suggesting the substantial adjuvant effect of flagellin [65, 66].